Amicus (FOLD) is focused on the following key strategic priorities in 2024: Delivering double-digit Galafold revenue growth; Executing multiple successful launches of Pombiliti + Opfolda; Advancing ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases; Achieving full-year non-GAAP profitability
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD: